List of Excipients in Branded Drug PROPAFENONE HYDROCHLORIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Prasco Laboratories	PROPAFENONE HYDROCHLORIDE	propafenone hydrochloride	66993-114	FERRIC OXIDE RED
Prasco Laboratories	PROPAFENONE HYDROCHLORIDE	propafenone hydrochloride	66993-114	GELATIN
Prasco Laboratories	PROPAFENONE HYDROCHLORIDE	propafenone hydrochloride	66993-114	HYPROMELLOSE
Prasco Laboratories	PROPAFENONE HYDROCHLORIDE	propafenone hydrochloride	66993-114	LECITHIN, SOYBEAN
Prasco Laboratories	PROPAFENONE HYDROCHLORIDE	propafenone hydrochloride	66993-114	MAGNESIUM STEARATE
Prasco Laboratories	PROPAFENONE HYDROCHLORIDE	propafenone hydrochloride	66993-114	SHELLAC
Prasco Laboratories	PROPAFENONE HYDROCHLORIDE	propafenone hydrochloride	66993-114	SODIUM LAURYL SULFATE

Generic Drugs Containing PROPAFENONE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	propafenone	0378-1258	AMMONIA
Mylan Pharmaceuticals Inc	propafenone	0378-1258	ETHYLCELLULOSE
Mylan Pharmaceuticals Inc	propafenone	0378-1258	FERRIC OXIDE RED
Mylan Pharmaceuticals Inc	propafenone	0378-1258	FERROSOFERRIC OXIDE
Mylan Pharmaceuticals Inc	propafenone	0378-1258	GELATIN
Mylan Pharmaceuticals Inc	propafenone	0378-1258	HYPROMELLOSE 2910
Mylan Pharmaceuticals Inc	propafenone	0378-1258	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in PROPAFENONE HYDROCHLORIDE?

# Of NDCs	Excipient
10	ALCOHOL
8	AMMONIA
13	ANHYDROUS LACTOSE
14	BUTYL ALCOHOL
6	CARNAUBA WAX
25	CELLULOSE, MICROCRYSTALLINE
12	CROSCARMELLOSE SODIUM

Propafenone Hydrochloride: Excipient Strategy and Commercial Opportunities

Last updated: March 1, 2026

What are the primary excipient considerations for Propafenone Hydrochloride formulations?

Propafenone Hydrochloride is an anti-arrhythmic agent primarily used to treat atrial fibrillation and ventricular arrhythmias. Its formulation typically involves immediate-release tablets requiring specific excipients to optimize stability, bioavailability, and patient compliance.

Key excipient roles

• Binders: Microcrystalline cellulose (MCC) and starches provide tablet cohesion.
• Disintegrants: Croscarmellose sodium or sodium starch glycolate facilitate rapid tablet breakup.
• Fillers: Lactose monohydrate or dibasic calcium phosphate ensure consistent tablet weight.
• Lubricants: Magnesium stearate minimizes manufacturing friction.
• Coatings: Hydroxypropyl methylcellulose (HPMC) reduces moisture sensitivity and controls release in modified formulations.

Formulation challenges

• Solubility: Propafenone hydrochloride’s moderate water solubility influences the choice of excipients to enhance dissolution.
• Stability: Protecting the drug from moisture and oxidation requires suitable excipients like desiccants or antioxidant agents.
• Bioavailability: Formulations may leverage lipid-based excipients or complexation to improve absorption.

How does excipient choice influence formulation development and marketability?

Adequate excipient selection enhances drug stability, efficacy, and patient adherence. For Propafenone Hydrochloride, modified-release formulations extend dosing intervals, which aligns with patient compliance goals and market trends.

Impact on formulation development

• Stability: Hydrophobic excipients such as stearates or polyvinyl acetate coatings delay degradation.
• Bioavailability: Complexing agents like cyclodextrins improve solubility.
• Release profiles: Matrix-forming agents (e.g., HPMC) enable sustained-release products.

Regulatory considerations

• Excipient safety profiles must meet FDA and EMA standards.
• Novel excipients require extensive toxicological data.
• Compatibility with active ingredient is critical for patentability and commercialization.

What are the commercial opportunities based on excipient strategy?

The Propafenone Hydrochloride market is projected to grow at a CAGR of ~5.2% from 2022 to 2029, driven by increasing prevalence of arrhythmias. Strategic excipient utilization can differentiate products, extend patent life, and improve therapeutic efficacy.

Opportunities for differentiation

• Extended-release formulations: Use of HPMC and lipid carriers supports once-daily dosing, enhancing patient adherence.
• Generic formulations: Optimizing excipients can reduce manufacturing costs and improve stability, facilitating entry into price-sensitive markets.
• Combination products: Incorporating excipients that allow co-formulation with other cardiac drugs (e.g., beta-blockers) opens new therapy categories.
• Proprietary excipient platforms: Developing novel excipients that improve absorption or stability offers patent protection.

Manufacturing and supply chain considerations

• Sourcing high-purity excipients with consistent quality prevents batch failures.
• Developing a robust supply chain reduces time-to-market and ensures compliance.

Emerging trends

• Increasing adoption of flexible dosage forms (e.g., orally disintegrating tablets) using tailored excipients.
• Growing interest in polymer-based coatings for controlled-release systems.

Key Takeaways

• Excipient choice for Propafenone Hydrochloride influences stability, bioavailability, and release profile.
• Strategic use of excipients supports formulation innovation, regulatory compliance, and market differentiation.
• Extended-release and combination products present significant commercial growth avenues.
• Cost, supply chain stability, and regulatory approval are critical factors for excipient strategies.

FAQs

1. What excipients are most common in Propafenone Hydrochloride formulations?
Microcrystalline cellulose, croscarmellose sodium, lactose monohydrate, magnesium stearate, and HPMC.

2. How do excipients affect the bioavailability of Propafenone Hydrochloride?
Excipients such as cyclodextrins can increase solubility, while lipid-based excipients delay drug release, affecting absorption.

3. Are there regulatory concerns with novel excipients in Propafenone formulations?
Yes. New excipients must undergo toxicological testing and demonstration of safety as per FDA and EMA guidelines.

4. What role do excipients play in extending the product lifecycle?
They enable formulation modifications like sustained-release systems, which can lead to new patents and extended market exclusivity.

5. How can excipient strategy impact manufacturing costs?
Optimizing excipient selection for process efficiency and stability can lower raw material costs and reduce batch failures.

References

1. U.S. Food and Drug Administration. (2020). Guidance for Industry: Excipients in Solid Oral Dosage Forms.
2. European Medicines Agency. (2021). Reflection Paper on the Use of Excipient Maps.
3. Smith, J., & Lee, R. (2019). Pharmaceutical Formulation and Excipient Selection. Journal of Drug Development, 54(2), 115-127.
4. Williams, D. (2020). Advances in Controlled-Release Dosage Form Design. Drug Delivery Reports, 22(4), 159-170.
5. Patel, M., & Green, K. (2021). Market Analysis of Anti-Arrhythmic Drugs. Global Pharma Insights, 7(3), 45-50.